biology

Crovalimab

Crovalimab is a biology topic covered in the lgStudy science library. This page brings together a partial reference excerpt, illustrations, worked examples, real-world applications and a short study plan, so you can understand Crovalimab rather than just read about it. In short: Crovalimab, sold under the brand name Piasky, is a monoclonal antibody used for the treatment of people with paroxysmal nocturnal hemoglobinuria. It is a complement component 5 (C5) inhibitor.

Key takeaways

Crovalimab belongs to biology; place it in that map before memorising details.
Learn the definition first, then one example that makes the definition concrete.
Connect Crovalimab to a quantity you can measure, compute or draw — that is where exam questions come from.
Reproduce the core statement of Crovalimab from memory before moving on to harder problems.

Reference excerpt

Crovalimab, sold under the brand name Piasky, is a monoclonal antibody used for the treatment of people with paroxysmal nocturnal hemoglobinuria. It is a complement component 5 (C5) inhibitor. Crovalimab was approved for use in China in February 2024, in Japan in April 2024, in the United States in June 2024, and in the European Union in August 2024. It was developed and is marketed by Roche/Genentech.

Medical uses In the US, crovalimab is indicated for the treatment of people aged 13 years of age and older with paroxysmal nocturnal hemoglobinuria and body weight of at least 40 kilograms (88 lb).

Adverse effects The US Food and Drug Administration (FDA) label for crovalimab contains a boxed warning about the increased risk of Neisseria meningitidis infection, which can be life-threatening.

History

Clinical trials Three phase III clinical trials have evaluated crovalimab in both people who were C5 inhibitor–naive and those switching to crovalimab from other C5 inhibitors. COMMODORE 1 is a phase III randomized clinical trial comparing crovalimab vs eculizumab in people with paroxysmal nocturnal hemoglobinuria treated with C5 inhibitors. COMMODORE 1 examines the safety, tolerability and pharmacokinetic/pharmacodynamic properties of crovalimab in PNH patients switching from eculizumab. The study showed that crovalimab maintained disease control in PNH patients switching from eculizumab. COMMODORE 2 is a phase III randomized trial comparing crovalimab vs eculizumab in people with paroxysmal nocturnal hemoglobinuria who are naive to C5 inhibitor treatment. COMMODORE 2 was positive for its co-primary endpoints, transfusion avoidance and hemolysis control (measured lactate dehydrogenase levels) which are disease control indicators, and its data shows crovalimab is non-inferior to eculizumab. COMMODORE 3 is a phase III single-arm trial run in China, studying crovalimab in C5 inhibitor-naive people with paroxysmal nocturnal hemoglobinuria. COMMODORE 3 assessed the safety, efficacy, pharmacokinetics, and pharmacodynamics of crovalimab in people with C5-naive paroxysmal nocturnal hemoglobinuria. The study met the co-primary efficacy endpoints of haemolysis control and transfusion avoidance.

Society and culture

Legal status Crovalimab was approved for use in China in February 2024, and in Japan in April 2024. Crovalimab was approved for medical use in the United States in June 2024. In June 2024, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Piasky, intended as monotherapy for the treatment of people twelve years of age or older with a weight of 40 kilograms (88 lb) and above with paroxysmal nocturnal haemoglobinuria. The applicant for this medicinal product is Roche Registration GmbH. Crovalimab was authorized for medical use in the European Union in August 2024.

Names Crovalimab is the international nonproprietary name.

Research Crovalimab is the subject of five phase III studies for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome (aHUS). It is also being investigated for the treatment of sickle cell disease and other conditions.

References

External links "Crovalimab (Code C169867)". NCI Thesaurus. Archived from the original on 25 November 2023.

Worked examples

Example 1 — a first encounter with Crovalimab

Start with the simplest possible case. Write down what Crovalimab claims or describes in one sentence, then invent the smallest concrete situation in which that sentence is true. In biology, the smallest case is usually a single object, a single equation or a single measurement. Check that every symbol or term in your sentence has a meaning in that case.

Example 2 — changing one variable

Take the situation from Example 1 and change exactly one quantity: double it, halve it, or set it to zero. Predict what should happen to Crovalimab before you calculate. Comparing your prediction with the result is the fastest way to find out whether you understand the idea or only the words.

Example 3 — an exam-style question

Typical questions about Crovalimab ask you to (a) state it precisely, (b) apply it to given data, and (c) explain a limitation. Practise writing all three answers in under five minutes; the third part is what separates a full-mark answer from an average one.

Applications of Crovalimab

In research: Crovalimab appears in biology research whenever the underlying quantities have to be modelled precisely. Papers usually cite it as a starting assumption and then explore where it breaks down.
In technology and industry: Engineering practice reuses Crovalimab in design rules, simulations and safety margins. Knowing the idea lets you read a specification sheet and understand why the numbers look the way they do.
In the classroom: Crovalimab is common in secondary-school and first-year university syllabi. It links to neighbouring topics Drugs developed by Genentech, Monoclonal antibodies, Roche, so understanding it makes those chapters shorter.
In everyday life: Look for Crovalimab outside the textbook — in sport, cooking, traffic, electronics or the sky above you. An example you found yourself is remembered far longer than one you were given.

Affiliate

Preply — study more efficiently by working with a personal tutor. 50% off.

How to study Crovalimab in 20 minutes

Read the reference excerpt below once, without taking notes.
Close the page and write down what Crovalimab means in your own words.
Compare your version with the excerpt and mark what you missed.
Work through the three examples above with pen and paper.
Explain Crovalimab out loud to somebody else — or to Teacher Smith in the lgStudy chat.

Frequently asked questions

What is Crovalimab in simple terms?

Crovalimab, sold under the brand name Piasky, is a monoclonal antibody used for the treatment of people with paroxysmal nocturnal hemoglobinuria. It is a complement component 5 (C5) inhibitor.

Why does Crovalimab matter?

Because it connects several biology ideas at once: it gives you a definition you can apply, a quantity you can calculate, and a way to check whether a result is plausible.

How should I study Crovalimab?

Read the excerpt, restate it from memory, then work through the examples and applications listed on this page. The five-step study plan above takes about twenty minutes.

What does this page cover?

It gives you a compact reference excerpt plus original lgStudy explanations, examples, applications and study material on Crovalimab.